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BACKGROUND	  
Generally	  speaking,	  Rheumatoid	  Arthritis	  is	  an	  autoimmune	  disease	  that	  normally	  presents	  itself	  during	  adulthood,	  within	  the	  ages	  of	  30-­‐50	  years	  old11.	  Currently,	  it	  affects	  more	  than	  1.3	  million	  people	  within	  the	  United	  States	  alone,	  with	  70%	  of	  Rheumatoid	  Arthritis	  patients	  being	  female11.	  The	  disease	  results	  in	  chronic,	  systemic	  inflammation	  in	  which	  the	  immune	  system	  is	  attacking	  healthy	  tissues.	  It	  typically	  affects	  small	  synovial	  joints	  such	  as	  those	  in	  the	  hands	  and	  feet	  but	  also	  has	  the	  ability	  to	  impact	  shoulders,	  hips	  and	  other	  tissues	  and	  organs12.	  	  Clinically,	  it	  is	  described	  using	  the	  following	  criteria:	  the	  presence	  of	  four	  or	  more	  of	  the	  following	  factors	  for	  a	  duration	  of	  no	  less	  than	  six	  weeks	  “1.	  morning	  stiffness	  in	  and	  around	  joints	  lasting	  at	  least	  1	  hour	  before	  maximal	  improvement;	  2)	  soft	  tissue	  swelling	  (arthritis)	  of	  3	  or	  more	  joint	  areas	  observed	  by	  a	  physician;	  3)	  swelling	  (arthritis)	  of	  the	  proximal	  interphalangeal,	  metacarpophalangeal,	  or	  wrist	  joints;	  4)	  symmetric	  swelling	  (arthritis);	  5)	  rheumatoid	  nodules;	  6)	  the	  presence	  of	  rheumatoid	  factor;	  and	  7)	  radiographic	  erosions	  and/or	  periarticular	  osteopenia	  in	  hand	  and/or	  wrist	  joints1.	  	  	  	  	  Symptoms	  include	  pain,	  swelling	  and	  stiffness	  of	  the	  affected	  joints	  with	  the	  pain	  tending	  to	  be	  worse	  after	  being	  sedentary	  for	  long	  periods	  of	  time12.	  Rheumatoid	  nodules	  also	  can	  form	  around	  the	  affected	  areas	  within	  the	  joints12.	  In	  addition	  to	  symptoms	  directly	  impacting	  the	  affected	  area,	  loss	  of	  energy,	  low	  fever,	  weight	  loss,	  and	  a	  shortage	  of	  red	  blood	  cells	  are	  also	  symptoms	  that	  present	  themselves	  in	  rheumatoid	  arthritis	  patients12.	  	  Currently,	  there	  is	  no	  cure	  for	  Rheumatoid	  Arthritis	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because	  much	  is	  still	  unknown	  about	  the	  disease	  mechanism	  and	  there	  are	  multiple	  factors	  that	  have	  been	  proposed	  to	  contribute	  to	  the	  disease.	  However,	  many	  treatments	  are	  available	  to	  sufferers.	  Patients	  are	  generally	  started	  on	  DMARDs	  (disease-­‐modifying	  antirheumatic	  drugs)	  that	  act	  to	  slow	  the	  progression	  of	  the	  disease13.	  	  Methotrexate,	  Leflunomide,	  Hydroxychloroquine	  and	  Sulfasalzine	  are	  just	  a	  few	  of	  the	  DMARDs	  that	  are	  commonly	  prescribed	  to	  patients13.	  In	  addition	  to	  DMARDs,	  individuals	  may	  also	  be	  advised	  to	  take	  anti-­‐inflammatory	  drugs	  as	  needed	  in	  order	  to	  alleviate	  pain	  caused	  by	  and	  in	  addition	  to	  the	  swelling13.	  	  No	  single	  treatment	  will	  work	  for	  every	  patient	  and	  thus	  doctors	  and	  patients	  must	  work	  closely	  together	  in	  order	  to	  create	  a	  customized,	  individual	  plan	  on	  a	  patient-­‐by-­‐patient	  basis.	  	  	  	  It	  is	  important	  to	  know	  that	  Rheumatoid	  Arthritis	  patients	  do	  run	  the	  risk	  of	  death	  attributed	  to	  the	  disease10.	  	  In	  1987	  a	  long-­‐term	  study	  was	  preformed	  on	  Rheumatoid	  Arthritis	  patients.	  The	  researchers	  observed	  an	  increase	  in	  patient	  comfort	  levels	  and	  a	  decrease	  in	  bone	  degradation	  for	  first	  ten	  years	  but	  observed	  a	  decline	  in	  patient	  comfort	  and	  bone	  mass	  levels	  the	  following	  years.	  	  By	  twenty	  years,	  the	  researchers	  had	  found	  35%	  of	  their	  patients	  to	  be	  dead	  with	  it	  often	  being	  due	  to	  the	  disease10.	  	  Often	  times	  this	  detail	  escapes	  the	  minds	  of	  the	  general	  public	  when	  faced	  with	  the	  term	  Rheumatoid	  Arthritis	  because	  the	  focus	  is	  on	  treatment	  of	  pain	  and	  swelling	  in	  the	  joints	  but	  there	  is	  a	  high	  risk	  of	  mortality	  and	  disability	  associated	  with	  the	  disease11.	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Immunologically	  speaking,	  Rheumatoid	  Arthritis	  is	  considered	  by	  many	  a	  type	  IV	  hypersensitivity	  autoimmune	  disease.	  Type	  IV	  hypersensitivities	  are	  often	  referred	  to	  as	  a	  delayed-­‐type	  hypersensivity	  because	  they	  are	  cell-­‐mediated,	  as	  opposed	  to	  antibody-­‐mediated,	  and	  thus	  take	  time	  to	  develop.	  In	  the	  immunological	  response,	  the	  antigen	  is	  present	  on	  major	  histocompatibility	  complex	  (MHC)	  type	  II-­‐coded	  proteins	  that	  are	  expressed	  on	  macrophage	  cell	  surfaces.	  The	  MHC,	  called	  HLA	  in	  humans	  is	  a	  large	  gene	  gamily	  located	  on	  the	  short	  arm	  of	  chromosome	  number	  6.	  In	  	  a	  normal	  response,	  antigen	  presenting	  cells	  (APC)	  such	  as	  macrophages,	  dendritic	  cells,	  and	  B	  cells	  identify	  and	  phagocytose	  pathogens	  and	  infected	  cells	  that	  are	  displaying	  non-­‐self	  antigens.	  Once	  the	  foreign	  particle	  or	  damaged	  cells	  are	  digested,	  they	  are	  displayed	  on	  the	  surface	  MHC	  class	  II	  thereby	  activating	  additional	  cells	  of	  the	  immune	  system,	  producing	  cytokines,	  activating	  complement	  pathways,	  and	  other	  mechanisms	  in	  order	  to	  eliminate	  foreign	  particles.	  In	  the	  case	  of	  Rheumatoid	  Arthritis,	  the	  APCs	  of	  the	  body	  are	  believed	  to	  display	  a	  self-­‐antigen	  on	  their	  MHC	  class	  II	  and	  elicit	  an	  inappropriate	  immune	  response.	  	  	  With	  antigen	  bound	  to	  MHC	  II,	  macrophages	  are	  stimulated	  to	  produce	  IL-­‐12	  in	  order	  to	  stimulate	  CD	  4+	  helper	  T	  cell’s	  proliferation	  and	  recruitment,	  thus	  intensifying	  the	  immune	  response.	  During	  the	  interaction	  with	  the	  antigen,	  CD	  4+	  helper	  T	  cells	  type	  I	  (Th1)	  are	  stimulated	  and	  produce	  cytokines	  such	  as	  interluekin-­‐2	  and	  interferon	  gamma.	  	  Interluekin-­‐2	  stimulates	  the	  proliferation,	  differentiation,	  and	  growth	  of	  neighboring	  T	  cells.	  Interferon	  gamma	  is	  responsible	  for	  the	  activation	  of	  macrophages,	  and	  is	  critical	  for	  immunological	  responses	  to	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intracellular	  bacteria,	  viruses,	  and	  tumor	  cells.	  Interferon	  gamma	  in	  atypical	  quantities	  has	  been	  proposed	  to	  lead	  to	  auto	  inflammatory	  and	  autoimmune	  diseases	  such	  as	  Rheumatoid	  Arthritis.	  The	  symptoms	  caused	  by	  Rheumatoid	  Arthritis	  are	  thus	  due	  to	  the	  swelling	  that	  the	  inappropriate	  immunological	  response	  mediates.	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ABSTRACT	  
Overproduction	  of	  nitric	  oxide	  causes	  oxidative	  stress	  in	  joint	  tissues.	  Under	  this	  stress,	  synovial	  cells	  are	  more	  prone	  to	  pro-­‐inflammatory	  cytokine	  stimulation,	  which	  could	  result	  in	  the	  development	  of	  Rheumatoid	  Arthritis.	  This	  laboratory	  has	  discovered	  that	  a	  HLA	  class	  II-­‐encoded	  sequence	  called	  the	  ‘shared	  epitope’	  is	  functioning	  as	  a	  signal	  transduction	  ligand	  that	  activates	  nitric	  oxide	  production	  in	  cells.	  Previous	  studies	  have	  shown	  that	  a	  synthetic	  linear	  peptide	  expressing	  the	  shared	  epitope	  sequence	  can	  induce	  the	  production	  of	  nitric	  oxide	  in	  cells.	  They	  have	  begun	  testing	  different	  concentrations	  of	  cyclic	  peptides	  (derived	  from	  the	  shared	  epitope	  sequence)	  in	  order	  to	  check	  if	  cyclic	  peptides	  maintain	  the	  same	  ability	  to	  trigger	  nitric	  oxide	  signaling	  as	  the	  linear	  counterpart;	  cyclic	  peptides	  have	  longer	  half-­‐lives	  than	  linear	  peptides.	  	  For	  detecting	  nitric	  oxide	  response	  in	  cells,	  DAF-­‐2	  DA	  dye	  is	  loaded	  into	  M1	  cells	  at	  370C	  for	  1	  hour;	  then	  cells	  are	  treated	  with	  different	  concentrations	  of	  cyclic	  peptides.	  Linear	  peptides	  are	  used	  as	  positive	  control,	  and	  no	  peptide	  treatment	  as	  the	  negative	  control.	  Nitric	  oxide	  levels	  are	  continually	  monitored	  by	  a	  fluorescence	  micro-­‐plate	  reader	  during	  an	  eight	  hour	  time	  period.	  The	  results	  obtained	  from	  this	  experiment	  will	  be	  used	  to	  design	  a	  cyclic	  peptide	  to	  stimulate	  the	  signaling	  cascade	  that	  leads	  to	  the	  increase	  of	  nitric	  oxide	  in	  cells.	  Eventually,	  these	  data	  will	  help	  us	  to	  further	  understand	  the	  genetic	  causes	  of	  Rheumatoid	  Arthritis.	  	  	  It	  has	  been	  previously	  proposed	  by	  scientists	  in	  this	  group	  that	  calreticulin	  (CRT)	  plays	  an	  important	  role	  in	  Rheumatoid	  Arthritis	  due	  to	  its	  ability	  to	  transduce	  
	   8	  
shared	  epitope	  activated	  signaling	  within	  the	  cell2.	  In	  order	  to	  assess	  the	  levels	  to	  which	  calreticulin	  enhances	  signaling	  within	  the	  cell,	  DAF-­‐2DA	  dye	  is	  loaded	  into	  MEF	  K42	  cells	  at	  370C	  for	  1	  hour;	  then	  cells	  are	  treated	  with	  different	  concentrations	  of	  calreticulin,	  as	  well	  as	  65-­‐79*0401	  (shared	  epitope)	  	  and	  65-­‐79*0402	  (control)	  peptide.	  The	  cells	  treated	  with	  no	  calreticulin	  as	  well	  as	  65-­‐79*0401,	  65-­‐79*0402,	  and	  no	  peptide	  are	  used	  as	  negative	  control	  as	  well	  as	  the	  cells	  treated	  with	  varying	  concentrations	  of	  calreticulin	  and	  100	  ng/ul	  65-­‐79*0401	  and	  65-­‐79*0402.	  A	  fluorescence	  microplate	  reader	  recorded	  the	  nitric	  oxide	  levels	  produced	  by	  the	  cells	  over	  an	  eight	  hour	  time	  period.	  The	  results	  from	  this	  experiment	  will	  be	  used	  in	  order	  to	  asses	  the	  effect	  calreticulin	  has	  on	  shared	  epitope	  signaling	  cascades	  in	  cells,	  which	  will	  be	  used	  to	  further	  understand	  the	  genetic	  causes	  of	  Rheumatoid	  Arthritis.	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INTRODUCTION	  
Individuals	  carrying	  shared	  epitope	  positive	  genes	  have	  been	  found	  to	  be	  more	  prone	  to	  Rheumatoid	  Arthritis	  and	  other	  autoimmune	  diseases	  in	  comparison	  to	  individuals	  lacking	  the	  shared	  epitope	  sequence3.	  	  When	  speaking	  about	  the	  shared	  epitope	  (SE),	  we	  specifically	  refer	  to	  the	  MHC	  II	  HLA-­‐DRB1	  alleles	  that	  code	  a	  five-­‐amino	  acid	  sequence	  motif	  in	  positions	  70–74	  of	  the	  HLA-­‐DRβ	  chain:	  QKRAA,	  QRRAA,	  or	  RRRAA8.	  The	  disease	  in	  shared	  epitope-­‐positive	  patients	  begins	  earlier	  and	  is	  more	  erosive	  than	  in	  shared	  epitope-­‐negative	  individuals3.	  Furthermore,	  there	  is	  evidence	  supporting	  gene-­‐dose	  effect,	  whereby	  the	  severity	  of	  bone	  destruction	  in	  Rheumatoid	  Arthritis	  correlates	  positively	  with	  the	  number	  of	  shared	  epitope-­‐coding	  HLA-­‐DRB1	  alleles7.	  	  	  Dr.	  Holoshitz’s	  lab	  has	  recently	  found	  that	  the	  SE	  functions	  as	  an	  allele-­‐specific	  signal	  transducing	  ligand	  that	  activates	  a	  nitric	  oxide	  (NO)	  mediated	  pro-­‐oxidative	  cell	  signaling,	  as	  well	  as	  an	  innate	  immune	  signaling	  pathway	  in	  other	  cells.	  The	  data	  collected	  from	  Denise	  De	  Almedia,	  Song	  Ling,	  Xiujun	  Pi,	  Anne	  Hartmann-­‐Scruggs,	  Paul	  Pumpenst	  and	  Joseph	  Holoshitz	  have	  shown	  that	  regardless	  if	  the	  shared	  epitope	  is	  expressed	  in	  its	  native	  conformation	  on	  the	  cell	  surface,	  as	  a	  cell-­‐free	  HLA-­‐DR,	  inserted	  into	  large	  recombinant	  proteins,	  or	  as	  short	  synthetic	  peptides	  it	  activates	  nitric	  oxide	  mediated	  signaling4.	  	  This	  enforces	  the	  ligand-­‐binding	  theory	  in	  which	  the	  shared	  epitope	  acts	  as	  a	  ligand	  to	  bind	  to	  a	  cellular	  receptor	  that,	  once	  activated,	  induces	  nitric	  oxide	  signaling	  within	  cells7.	  The	  receptor	  to	  which	  the	  shared	  epitope	  sequence	  has	  been	  found	  to	  bind	  is	  calreticulin.	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  Calreticulin	  (CRT)	  is	  a	  multifunctional	  calcium-­‐binding	  protein	  originally	  defined	  as	  an	  endoplasmic	  reticulum	  molecular	  chaperone.	  Intracellularly,	  calreticulin	  plays	  an	  important	  role	  in	  the	  transport	  of	  incorrectly	  folded	  proteins	  out	  of	  the	  ER	  so	  that	  they	  may	  be	  degraded,	  instead	  of	  being	  further	  transported2.	  However,	  it	  has	  more	  recently	  been	  shown	  that	  calreticulin	  is	  also	  expressed	  extracellularly	  and	  attaches	  to	  the	  surface	  of	  many	  cells	  where	  it	  is	  involved	  in	  signal	  transduction	  events	  associated	  with	  innate	  immunity,	  cell	  adhesion,	  and	  apoptosis2.	  Calreticulin	  plays	  an	  important	  role	  in	  a	  cell’s	  pro	  or	  anti-­‐inflammatory	  response	  due	  to	  its	  role	  in	  the	  elimination	  of	  apoptotic	  cells4.	  During	  apoptosis,	  a	  second	  set	  of	  signals	  is	  released	  by	  apoptotic	  cells	  that	  cause	  the	  appropriate	  inflammatory	  response	  within	  the	  cell.	  It	  has	  previously	  been	  postulated	  that	  defective	  clearance	  of	  apoptotic	  cells	  has	  been	  a	  cause	  of	  autoantibody	  production.	  Apoptotic	  cells	  release	  danger	  signals	  and	  provide	  self-­‐antigens	  for	  aberrant	  presentation	  by	  dendritic	  cells4.	  Calreticulin	  plays	  a	  pivotal	  role	  in	  the	  junction	  between	  tolerance	  and	  autoimmunity	  due	  to	  its	  effects	  on	  the	  clearance	  of	  apoptotic	  cellular	  products	  and	  cells4.	  	  	  With	  respect	  to	  calreticulin’s	  role	  in	  the	  ligand-­‐binding	  theory	  of	  Rheumatoid	  Arthritis,	  the	  signaling	  pathway	  that	  occurs	  is	  mediated	  via	  the	  interaction	  between	  the	  shared	  epitope	  sequence	  and	  an	  extracellular	  surface	  receptor,	  which	  is	  proposed	  to	  be	  calreticulin.	  This	  protein	  serves	  as	  the	  signal-­‐transducing	  receptor	  present	  on	  the	  surface	  of	  many	  cells.	  Importantly,	  calreticulin	  is	  expressed	  on	  dendritic	  cells,	  which	  are	  believed	  to	  play	  a	  role	  in	  the	  pathogenesis	  of	  Rheumatoid	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Arthritis4.	  The	  shared	  epitope	  binding	  site	  on	  calreticulin	  has	  previously	  been	  mapped	  to	  the	  amino	  acid	  residues	  217-­‐223	  in	  the	  P-­‐domain2.	  Upon	  interaction	  with	  dendritic	  cells,	  the	  shared	  epitope	  activates	  immune	  regulatory	  events	  that	  have	  been	  shown	  to	  increase	  secretion	  of	  Il-­‐6	  and	  Il-­‐23	  as	  well	  as	  to	  facilitate	  generation	  of	  Th17	  cells;	  a	  subset	  of	  cells	  that	  play	  a	  role	  in	  autoimmunity2.	  	  Il-­‐6	  and	  Il-­‐6	  receptors	  have	  been	  found	  in	  high	  concentrations	  in	  rheumatoid	  arthritis	  patients	  within	  the	  synovial	  fluid	  and	  lead	  to	  the	  formation	  of	  Osteoclast	  like	  cell	  formations9.	  Osteoclasts	  are	  the	  cells	  that	  are	  primarily	  responsible	  for	  the	  degradation	  of	  bone	  and	  join	  tissue.	  With	  an	  increase	  in	  Il-­‐6	  caused	  by	  the	  shared	  epitope	  and	  calreticulin	  interaction,	  higher	  bone	  degradation	  has	  been	  observed	  due	  to	  the	  increase	  in	  Osteoclast	  like	  cells,	  thus	  leading	  to	  the	  characteristic	  bone	  degradation	  present	  in	  Rheumatoid	  Arthritis	  patients9.	  	  	  In	  addition	  to	  the	  increased	  cytokine	  secretion,	  with	  the	  shared	  epitope	  bound	  to	  calreticulin	  high	  levels	  of	  nitric	  oxide	  are	  observed.	  When	  nitric	  oxide	  levels	  are	  high	  within	  the	  cell	  it	  leads	  to	  an	  increase	  in	  oxidative	  damage	  due	  to	  its	  antagonistic	  effects	  upon	  cAMP	  production,	  cAMP	  has	  been	  shown	  to	  have	  oxidative	  damage	  protection	  effects.	  High	  nitric	  oxide	  levels	  have	  also	  been	  shown	  to	  inhibit	  	  adenosine	  mediated	  anti-­‐oxidative	  pathways8.	  	  Inhibition	  of	  anti-­‐oxidative	  and	  repair	  pathways,	  increased	  cytokine	  secretion,	  Th17	  cell	  generation,	  in	  addition	  to	  nitric	  oxide	  being	  a	  reactive	  species	  itself	  and	  causing	  oxidative	  damage	  leads	  to	  the	  inflammatory	  effects	  and	  symptoms	  observed	  in	  individuals	  with	  Rheumatoid	  Arthritis.	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  In	  this	  study,	  we	  characterized	  a	  novel	  small	  shared	  epitope-­‐mimetic	  compound,	  
c(HS4-­‐4),	  containing	  the	  shared	  epitope	  primary	  sequence	  motif	  QKRAA,	  which	  was	  then	  synthesized	  using	  a	  backbone	  cyclization	  method.	  The	  experiment	  involving	  
c(HS4-­‐4)	  was	  employed	  to	  see	  if	  cell	  nitric	  oxide	  signaling	  could	  be	  induced	  with	  the	  cyclic	  peptide	  containing	  the	  shared	  epitope	  sequence,	  c(HS4-­‐4),	  and	  to	  the	  same	  extent	  as	  a	  synthesized	  linear	  peptide	  containing	  the	  sequence,65-­‐79*0401,	  is	  capable	  of	  inducing	  signaling.	  In	  this	  experiment	  the	  linear	  peptide	  65-­‐79*0401	  was	  used	  and	  compared	  against	  differing	  concentrations	  of	  the	  cyclic	  form	  in	  order	  to	  assess	  its	  potency	  and	  candidacy	  for	  the	  continuation	  of	  its	  use	  in	  further	  experiments	  involving	  the	  shared	  epitope	  sequence.	  	  	  	  The	  experiments	  involving	  calreticulin	  were	  designed	  in	  order	  to	  investigate	  the	  nitric	  oxide	  signaling	  response	  induced	  in	  cells	  when	  treated	  with	  calreticulin	  as	  well	  as	  the	  linear	  shared	  epitope	  sequence,	  and	  a	  linear	  sequence	  counterpart	  that	  was	  epitope	  negative,	  65-­‐79*0402.	  In	  comparing	  the	  differences	  between	  nitric	  oxide	  produced	  by	  cells	  with	  no	  treatment	  of	  calreticulin,	  calreticulin	  and	  65-­‐79*0402,	  and	  calreticulin	  and	  65-­‐79*0402,	  this	  experiment	  was	  employed	  in	  order	  to	  test	  the	  effects	  various	  calreticulin	  levels	  had	  on	  the	  nitric	  oxide	  signaling	  production	  of	  cells.	  As	  well	  as,	  to	  further	  the	  evidence	  that	  calreticulin	  acts	  as	  the	  extracellular	  surface	  receptor	  for	  shared	  epitope	  binding	  and	  signal	  production,	  the	  ligand-­‐binding	  hypothesis.	  	   	  







Figure 17. A. Shows the chemical formula for c(HS4-4). The chemical structure of 
c(HS4-4), a backbone cyclic peptide analog containing the shared epitope consensus 
motif QKRAA, was designed to induce a stable active conformation. A backbone 
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cyclization methodology was used to keep the functional groups of the side chain 
residues intact. This feature ensures that all the functional groups in a peptide sequence 
are available for biologic activity7. Figure 1.D shows the cyclic peptide, c(HS4-4) bound 
to the P domain of calreticulin with the key docking amino acids highlighted. A low-
power docking image of the c(HS4-4) compound (identified here in its sequence structure 
cQKRAA and shown in green) superimposed onto the previously identified SE binding 
site on the calreticulin P-domain (gray surface). Calreticulin amino acid residues 
previously found to play critical shared epitope ligand-binding roles (7) are highlighted in 
red7. E. A high-power view of c(HS4-4)–calreticulin molecular interactions7.  	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MATERIALS	  AND	  METHODS	  
c(HS4-­4)	  	  Human	  Fibroblast	  M1	  cell	  line	  was	  provided	  by	  Dr.	  Haseltine.	  The	  methods	  used	  to	  isolate,	  and	  purify	  this	  cell	  line	  can	  be	  found	  by	  referring	  to	  Experimental	  Cell	  Research	  1.51	  (1984)	  40&420.	  Synthetic	  peptides	  corresponding	  to	  position	  65–79	  on	  the	  HLA-­‐DRβ–	  chain,	  coded	  by	  the	  shared	  epitope-­‐positive	  allele	  DRB1*0401	  (sequence:	  65-­‐KDLLEQKRAAVDTYC-­‐79),	  were	  synthesized	  and	  purified	  (>90%)	  as	  we	  previously	  described5.	  The	  peptide	  70–74*0401	  (carrying	  the	  70-­‐QKRAA-­‐74	  sequence)	  was	  synthesized	  by	  the	  University	  of	  Michigan	  (Ann	  Arbor,	  MI)	  peptide	  synthesis	  core.	  Peptide	  0401	  is	  expressed	  as	  65-­‐79*0401;	  0402	  as	  65-­‐79*0402.	  Both	  of	  which	  are	  custom	  synthesized	  by	  Bio-­‐World	  Inc.	  The	  cyclic	  QKRAA,	  expressed	  as	  
c(HS4-­‐4),	  used	  in	  these	  experiments	  was	  used	  from	  Dr.	  Gibson’s	  lab.	  It	  is	  a	  backbone	  cyclic	  mimetic	  peptide,	  synthesized	  as	  explained	  previously7.	  
 
 Nitric	  Oxide	  (NO)	  Assay:	  3×	  104	  human	  fibroblasts	  were	  seeded	  in	  each	  well	  of	  96-­‐well	  plates	  one	  day	  before	  experiment	  in	  order	  to	  allow	  the	  cells	  to	  attach	  to	  the	  surface.	  The	  supernatant	  was	  removed	  and	  cells	  were	  washed	  with	  Phenol-­‐red	  free	  DMEM	  buffer	  once.	  Cells	  were	  first	  loaded	  with	  20	  µM	  of	  the	  fluorescent	  NO	  probe	  4,5-­‐diaminofluorescein	  diacetate	  (DAF-­‐2DA)	  in	  the	  dark	  at	  37°C	  for	  1	  hour.	  After	  dye	  loading,	  the	  supernatant	  was	  removed	  and	  the	  cells	  were	  washed	  once.	  Each	  well	  in	  the	  96-­‐	  well	  plate	  received	  50	  µl	  of	  Phenol-­‐red	  free	  medium	  and	  50	  µl	  of	  either	  more	  medium	  to	  act	  as	  control	  wells,	  the	  linear	  peptide,	  or	  the	  cyclic	  peptide	  in	  varying	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concentrations	  (0.1,1,	  10,100,1000	  µM).	  NO	  signal	  was	  recorded	  by	  using	  a	  Fusion	  αHT	  system	  at	  an	  excitation	  wavelength	  of	  488	  nm	  and	  emission	  wavelength	  of	  515	  nm.	  	  Reactive	  Oxygen	  Species	  (ROS)	  Assay:	  ROS	  production	  was	  quantified	  similarly,	  with	  the	  exception	  that	  cells	  were	  loaded	  with	  10µM	  CM-­‐H2DCFDA	  for	  30	  minutes.	  	  	  
CALRETICULIN	  In	  order	  to	  test	  the	  effects	  of	  calreticulin	  on	  MEF-­‐K42	  cells,	  a	  plasmid	  containing	  the	  human	  calreticulin	  gene	  was	  obtained	  from	  Dr.	  Raghavan’s	  lab.	  We	  then	  used	  GeneRunner	  in	  order	  to	  sequence	  the	  plasmid.	  We	  sequenced	  the	  plasmid	  in	  order	  to	  ensure	  there	  were	  no	  mutants	  introduced	  (See	  Figure	  1).	  Once	  the	  plasmid	  was	  sequenced	  and	  it	  was	  confirmed	  that	  there	  was	  no	  mutation	  in	  the	  human	  calreticulin	  gene,	  we	  moved	  on	  to	  transforming	  the	  plasmid	  containing	  human	  calreticulin	  into	  E.	  coli	  in	  order	  to	  express	  the	  calreticulin	  protein	  in	  larger	  amounts.	  The	  E.	  coli	  strain	  used	  was	  BL21(DE3).	  This	  particular	  strain	  was	  selected	  to	  be	  transformed	  because	  it	  contains	  no	  ampicillin	  resistance	  and	  is	  deficient	  in	  the	  proteases	  Lon	  and	  OmpT.	  Our	  plasmid	  carries	  a	  gene	  that	  confers	  ampicillin	  resistance,	  therefore	  allowing	  only	  E.	  coli	  colonies	  that	  have	  been	  successfully	  transformed	  with	  the	  plasmid	  to	  grow	  on	  the	  agar	  plate	  containing	  ampicillin.	  Cells	  from	  colonies	  on	  the	  agar	  plate	  were	  seeded	  in	  500	  mL	  of	  LB	  medium.	  We	  began	  to	  induce	  calreticulin	  protein	  expression	  by	  adding	  Isopropyl	  β-­‐D-­‐1-­‐
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thiogalactopyranoside	  (IPTG)	  to	  the	  medium.	  In	  order	  to	  purify	  the	  calreticulin	  protein	  from	  the	  E.	  coli,	  Lyszyme	  was	  used	  to	  break	  the	  cell	  wall.	  We	  then	  employed	  three	  freeze-­‐thaw	  cycles	  to	  break	  the	  cell	  membrane.	  We	  used	  centrifuge	  in	  order	  to	  separate	  the	  soluble	  protein	  from	  the	  debris	  of	  lysed	  cell	  solution.	  Our	  protein	  of	  interest	  was	  in	  the	  supernatant.	  We	  incubated	  the	  supernatant	  with	  a	  Nickel	  NTA	  column	  because	  there	  is	  a	  His6	  tag	  at	  the	  N-­‐terminus	  of	  Human	  calreticulin.	  Therefore,	  only	  His6-­‐calreticulin	  will	  bind	  to	  the	  nickel	  on	  the	  Nickel	  NTA	  column	  and	  the	  other	  protein	  will	  be	  washed	  away.	  In	  the	  final	  steps	  of	  purification,	  imidazole	  was	  used	  to	  remove	  His6-­‐calreticulinfrom	  the	  Nickel	  NTA	  column.	  In	  order	  to	  assess	  the	  purity	  of	  the	  collected	  calreticulin,	  the	  sample	  was	  ran	  on	  an	  SDS-­‐PAGE	  gel	  to	  confirm	  >	  90%	  purity.	  	  Protein	  concentration	  was	  determined	  by	  using	  a	  BCA	  protein	  assay	  kit.	  	  	  NO	  Assay:	  	  3×	  104	  MEF-­‐K42	  cells	  and	  the	  corresponding	  concentrations	  of	  calreticulin	  (4,	  1.5,	  0.5,	  0.2,	  0.1,	  or	  0	  ng/µl)	  were	  loaded	  into	  each	  well	  of	  96-­‐well	  plates	  one	  day	  before	  the	  experiment	  was	  ran	  in	  order	  to	  allow	  the	  cells	  to	  attach	  to	  the	  surface	  and	  to	  allow	  for	  the	  calreticulin	  to	  interact	  with	  the	  cells.	  The	  supernatant	  was	  removed	  and	  cells	  were	  washed	  with	  Phenol-­‐red	  free	  DMEM	  buffer.	  Cells	  were	  first	  loaded	  with	  20	  µM	  of	  the	  fluorescent	  NO	  probe	  4,5-­‐diaminofluorescein	  diacetate	  (DAF-­‐2DA)	  and	  then	  incubated	  in	  the	  dark	  at	  37°C	  for	  1	  hour.	  After	  dye	  loading,	  the	  supernant	  was	  removed	  and	  the	  cells	  were	  once	  again	  washed.	  Each	  well	  in	  the	  96-­‐	  well	  plate	  received	  50	  µl	  of	  Phenol-­‐red	  free	  medium	  and	  50	  µl	  of	  either	  more	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Protein	  Sequence	  	  
TEV	  protease	  cutting	  Site:	  ENLYFQ	  (G/S)	  
Histidine	  Tags	  
 
Figure 2. The calreticulin DNA sequence was found using GeneBlast, as was the amino 
acid sequence. GeneBlast was also used to find the sequence T7 plasmid sequence. 
Sequencing of these two components was critical in order to sequence our entire plasmid 
in order to ensure it was pure prior to transformation and protein amplification. Also 
while sequencing the plasmid we needed to ensure the presence of Histidine Tags, which 
are what was used to bind to the protein to the Nickel beads during purification. The TEV 
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Figure 3. The 96 well plate was designed to test a multitude of different conditions within 
a single read. For each read various levels of CRT were tested (4ng/ul, 1.5, 0.5, 0.2, 0.1, 
and 0) in order to see at which concentration the strongest response was recorded from 
the cells. Along with the various levels of CRT tested, the effects of CRT along with 65-
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RESULTS 
 
c(HS4-4)   
Analysis of the resulting NO and ROS assays showed that cells treated with 57µM of 65-
79*0401 and the cyclic peptide c(HS4-4) had higher relative NO production rates 
compared to the control cells.  This was seen by Fusion	  αHT	  machine	  recording	  higher	  NO	  for	  cells	  treated	  with	  65-­‐79*0401	  and	  c(HS4-­‐4)	  compared	  to	  the	  control	  cells.	   
The highest NO production rates were found at concentrations of 0.1 nM and 10nM of 
cyclic peptide c(HS4-4). Thus, further confirming that cells treated with cyclic and linear 
counterpart peptides produce more NO as opposed to cells without. The cyclic peptide in 
concentrations of 0.1 and 10 nM induced greater NO production in the M1 cells than the 
linear 57 µM 65-79*0401 peptide.  While cells treated with concentrations of 1, 100, and 
1000 nM had relative NO production rates lower than those of cells treated with 57 µM 
65-79*0401.   
 
The results obtained in this experiment further acted as evidence of the ligand-binding 
hypothesis because when the shared epitope is present it has been proposed to bind to a 
cell surface receptor. Once bound to the cell surface receptor (calreticulin), a signaling 
cascade has been proposed to occur through still unknown mechanisms in order to 
produce higher concentrations of NO5. With the increased levels of NO, higher rates and 
severity of oxidative damage has been shown to occur within cells due to blockage of 
oxidative damage repair pathways and an increase in reactive oxygen species5. The 
results from this experiment were published in The Journal of Immunology, “A Small 
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Shared Epitope–Mimetic Compound Potently Accelerates Osteoclast-Mediated Bone 






Figure 4. Figures 4A and 4B show the results of the experiments containing c(HS4-4) and 
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measured for the time spans in which a linear trend was observed. Both NO and ROS 
assays show that 65-79*0401 produces a higher NO output as opposed to control cells, 

































































Figure 4C: RAW 264.7 pre-OC cells (33104 per well) were plated in flat-bottom 96-well 
plates in the presence of various concentrations of c(HS4-4), and ROS production was 
measured over time7. The above NOS and ROS assays pictured above compare the 
relative NO production rates recorded from the M1 cells over a nine hour period treated 
with medium to serve as a control, 57 µM 65-79*0401, and differing concentrations of 
c(HS4-4). The above bar and line graphs were obtained from my publication, “A Small 
Shared Epitope–Mimetic Compound Potently Accelerates Osteoclast-Mediated Bone 
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CALRETICULIN	  The	  experiments	  involving	  calreticulin	  are	  in	  the	  preliminary	  stages.	  Our	  lab	  was	  excited	  to	  finally	  identify	  the	  cellular	  receptor	  and	  thus	  began	  our	  work	  right	  away	  using	  calreticulin	  for	  our	  experiments.	  In	  doing	  so,	  we	  were	  required	  to	  collect	  high	  amounts	  of	  purified	  calreticulin.	  Thus	  far,	  early	  data	  collected	  has	  shown	  that	  when	  calreticulin	  knock-­‐out	  MEF-­‐K42	  cells	  are	  loaded	  with	  calreticulin,	  we	  can	  observe	  a	  change	  in	  the	  nitric	  oxide	  signaling	  response.	  	  This	  can	  be	  seen	  by	  comparing	  the	  control	  group	  to	  all	  other	  concentrations	  of	  calreticulin	  in	  Figure	  6	  A	  and	  B.	  In	  doing	  so,	  one	  can	  see	  that	  cells	  that	  contained	  no	  calreticulin	  had	  higher	  levels	  of	  nitric	  oxide	  production	  compared	  to	  those	  at	  calreticulin	  concentrations	  of	  4	  ng/ul	  and	  1.5	  ng/ul.	  However,	  at	  concentrations	  lower	  than	  1.5	  ng/ul	  it	  was	  interesting	  to	  see	  a	  strong	  increase	  in	  nitric	  oxide	  production	  in	  cells	  treated	  with	  the	  shared	  epitope.	  Our	  lad	  had	  expected	  to	  see	  an	  increase	  in	  nitric	  oxide	  production	  as	  calreticulin	  levels	  increased	  to	  the	  point	  of	  saturation	  and	  is	  in	  the	  process	  of	  collaborating	  and	  designing	  experiments	  in	  order	  to	  test	  why	  we	  observed	  the	  opposite	  phenomenon.	  	  	  It	  can	  also	  be	  seen	  from	  the	  collected	  data	  that	  the	  shared	  epitope	  positive	  peptide,	  65-­‐79*0401,	  induces	  a	  higher	  nitric	  oxide	  signaling	  response	  as	  opposed	  to	  control	  cells	  and	  the	  shared	  epitope	  negative	  peptide,	  65-­‐79*0402.	  	  From	  concentrations	  of	  1.5	  ng/ul	  to	  0	  ng/ul	  it	  can	  clearly	  be	  seen	  that	  the	  shared	  epitope	  effected	  the	  amount	  of	  nitric	  oxide	  produced.	  At	  the	  lower	  levels	  of	  calreticulin,	  this	  effect	  is	  further	  amplified	  due	  to	  the	  calreticulin	  concentration	  dependency.	  Likewise,	  the	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A.  
 AVG SD SE 
4 hCRT Control 1.811588889 0.46047016 0.162800786 
4 hCRT 0401 1.794925212 0.562265651 0.229543991 
4 hCRT 0402 1.814533015 0.563003236 0.229845109 
1.5 hCRT Control 1.811588889 0.190969108 0.067517776 
1.5 hCRT 0401 1.986957433 0.150204959 0.061320918 
1.5 hCRT 0402 1.828591505 0.287155781 0.117230857 
0.5 hCRT Control 1.811588889 0.25226859 0.089190415 
0.5 hCRT 0401 2.402223118 0.327381065 0.13365276 
0.5 hCRT 0402 2.049073635 0.408269472 0.166675314 
0.2 hCRT Control 1.811588889 0.49756981 0.124392453 
0.2 hCRT 0401 2.416052668 0.542929716 0.156730309 
0.2 hCRT 0402 2.146868452 0.397624697 0.114784363 
0.1 hCRT Control 1.811588889 0.454146886 0.113536721 
0.1 hCRT 0401 2.89193216 0.783408427 0.226150533 
0.1 hCRT 0402 2.224702099 0.386085286 0.111453222 
0 hCRT Control 1.811588889 0.494663458 0.123665864 
0 hCRT 0401 2.203824534 0.804734157 0.268244719 
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B.  
 
Figure 6. Figure 6 A displays the various production rates of nitric oxide for each calreticulin concentration and it’s corresponding 0401, 0402, and control peptide 
subsets. The averages were calculated over a time span for which the data was found to 
be increasing linearly (thus data received from the ending times in which the cells were 
dying were not recorded and accounted for). This data was collected from averaging four 
experiments’ data. Figure 6B displays the relative NO production rates for the various 
concentrations of calreticulin tested along with 65-79*0401 and 65-79*0402 in MEF-
K42 cells. This graph is derived from the data presented in table Figure 5. A. Error bars 
were added to the graphs in order to show the variation among samples that were used to 
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DISCUSSION	  
The	  shared	  epitope	  sequence	  is	  the	  single	  most	  significant	  genetic	  risk	  factor	  for	  RA,	  but	  the	  mechanistic	  basis	  of	  its	  effect	  is	  unknown.	  Of	  interest,	  the	  shared	  epitope	  not	  only	  confers	  a	  higher	  risk	  for	  Rheumatoid	  Arthritis	  but	  also	  increases	  the	  likelihood	  of	  developing	  a	  more	  severe	  version	  of	  the	  disease7.	  Furthermore,	  there	  is	  evidence	  supporting	  gene-­‐dose	  effect,	  whereby	  the	  severity	  of	  bone	  destruction	  in	  Rheumatoid	  Arthritis	  positively	  correlates	  with	  the	  number	  of	  shared	  epitope-­‐coding	  HLA-­‐DRB1	  alleles7.	  	  	  Prior	  to	  my	  work	  in	  lab,	  it	  had	  previously	  been	  identified	  that	  the	  shared	  epitope	  sequence	  acts	  as	  a	  ligand	  for	  cell	  surface	  calreticulin	  that,	  once	  activated,	  induces	  nitric	  oxide	  mediated	  pro-­‐oxidative	  signaling.	  It	  has	  been	  proposed	  that	  the	  shared	  epitope	  has	  the	  ability	  to	  bind	  to	  the	  extracellular	  surface	  receptor,	  calreticulin,	  which	  causes	  receptor	  activation8.	  The	  activated	  receptor	  is	  then	  able	  to	  increase	  PKG	  levels	  through	  still	  unknown	  mechanisms,	  which	  then	  lead	  to	  an	  increase	  in	  nitric	  oxide.	  High	  nitric	  oxide	  levels	  within	  the	  cells	  have	  been	  shown	  to	  increase	  cellular	  susceptibility	  to	  oxidative	  damage	  by	  blocking	  the	  adenosine	  mediated	  anti-­‐oxidative	  pathway,	  as	  well	  as	  acting	  as	  an	  antagonist	  to	  cAMP	  production	  pathways8.	  With	  decreased	  levels	  of	  cAMP	  it	  has	  been	  observed	  the	  cells	  show	  a	  significant	  decrease	  in	  oxidative	  damage	  protection8.	  	  	  Previous	  work	  had	  demonstrated	  strong	  support	  for	  this	  ligand-­‐binding	  hypothesis	  for	  the	  effects	  of	  shared	  epitope-­‐Rheumatoid	  Arthritis;	  however,	  this	  previous	  work	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was	  done	  using	  linear	  shared-­‐epitope	  sequences.	  Linear	  peptides	  in	  solution	  were	  capable	  of	  taking	  on	  random	  conformations	  and	  were	  subject	  to	  a	  high	  level	  of	  degradation7.	  Therefore,	  the	  work	  for	  determining	  whether	  a	  backboned	  cyclic	  compound	  containing	  the	  shared	  epitope	  sequence	  could	  be	  created	  and	  act	  at	  a	  potency	  level	  close	  to	  that	  of	  our	  linear	  peptides	  became	  a	  necessity	  in	  order	  to	  further	  support	  the	  ligand-­‐binding	  hypothesis.	  When	  creating	  the	  backboned	  cyclic	  peptide,	  the	  lab	  was	  careful	  to	  create	  it	  keeping	  the	  primary	  amino	  acid	  sequence	  intact.	  This	  allowed	  the	  shared	  epitope	  sequence	  to	  remain	  in	  its	  native	  alpha	  helix	  secondary	  structure	  and	  protect	  itself	  against	  biodegradation.	  	  	  	  	  The	  beginning	  of	  this	  experimental	  process	  started	  with	  working	  on	  the	  cyclic,	  c(HS4-­‐4)	  versus	  linear,	  	  65-­‐79*0401,	  peptides	  and	  the	  potency	  at	  which	  they	  are	  capable	  of	  stimulating	  nitric	  oxide	  signaling	  in	  M1	  cells.	  	  The	  data	  collected	  from	  NO	  and	  ROS	  assays	  supports	  that	  peptide	  65-­‐79*0401	  induces	  nitric	  oxide	  production	  in	  human	  M1	  fibroblasts	  cells.	  The	  data	  also	  shows	  that	  the	  cyclic	  peptide	  is	  fully	  capable	  of	  producing	  relative	  NO	  production	  in	  rates	  exceeding	  those	  of	  the	  linear	  peptide	  65-­‐79*0401.	  10	  nM	  of	  the	  cyclic	  peptide	  has	  a	  more	  potent	  ability	  to	  stimulate	  NO	  signaling	  than	  the	  57	  µM	  linear	  peptide,	  indicating	  that	  the	  cyclic	  peptide	  is	  5000	  folds	  more	  potent	  than	  the	  linear	  peptide.	  It	  should	  be	  noted	  that	  the	  cyclic	  peptide	  has	  a	  more	  stable	  structure	  and	  longer	  half-­‐life	  than	  the	  linear	  peptide	  thus	  making	  it	  a	  better	  candidate	  for	  our	  continued	  research.	  The	  knowledge	  gained	  from	  these	  experiments	  is	  currently	  being	  used	  in	  studies	  with	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human	  dendritic	  cells	  in	  order	  to	  fully	  understand	  the	  signaling	  cascade	  that	  occurs	  in	  shared	  epitope	  positive	  individuals.	  	  	  The	  work	  with	  calreticulin	  allowed	  us	  to	  assess	  its	  purity	  within	  the	  sample	  plasmid	  we	  were	  given	  by	  Dr.	  Raghavan’s	  lab.	  Once	  determining	  its	  purity,	  we	  perfected	  ways	  in	  which	  to	  transform	  E.coli	  and	  to	  purify	  the	  cellular	  lysates	  for	  our	  desired	  sample	  by	  exploiting	  the	  use	  of	  histidine	  tags.	  The	  histidine	  tags	  were	  then	  removed	  by	  TEV	  protease	  before	  their	  use	  in	  cells.	  Once	  the	  sample	  was	  properly	  modified,	  we	  treated	  MEF-­‐K42	  cells	  with	  a	  variety	  of	  concentrations	  and	  found	  the	  most	  optimal	  range	  to	  be	  from	  4	  ng/ul	  to	  0	  ng/ul.	  This	  range	  is	  being	  used	  to	  continue	  our	  research	  in	  exposing	  calreticulin-­‐deficient	  cells	  to	  calreticulin.	  	  	  Results	  from	  the	  experiments	  showed	  that	  the	  linear	  peptide	  65-­‐79*0401	  produced	  the	  highest	  nitric	  oxide	  in	  comparison	  to	  the	  control	  peptide	  65-­‐79*0402-­‐treated	  cells.	  This	  demonstrates	  the	  importance	  of	  the	  shared	  epitope	  in	  nitric	  oxide	  cell	  signaling.	  In	  addition,	  the	  highest	  nitric	  oxide	  production	  levels	  were	  found	  to	  occur	  when	  cells	  were	  treated	  with	  0.5	  ng/ul	  –	  0.1	  ng/ul	  hCRT	  and	  65-­‐79*0401.	  This	  demonstrates	  that	  calreticulin	  plays	  a	  critical	  role	  in	  increasing	  nitric	  oxide	  signaling	  levels	  when	  the	  shared	  epitope	  sequence	  is	  present.	  These	  data	  strongly	  support	  the	  role	  that	  the	  interaction	  between	  the	  shared	  epitope	  and	  calreticulin	  together	  play	  in	  nitric	  oxide	  signaling.	  	  This	  study	  provides	  evidence	  of	  shared	  epitope-­‐calreticulin	  interaction	  and	  suggests	  that	  therapeutic	  targeting	  of	  this	  pathway	  should	  be	  considered	  when	  designing	  drugs	  in	  order	  to	  combat	  Rheumatoid	  Arthritis	  
	   32	  
symptoms	  in	  individuals	  who	  carry	  the	  shared	  epitope	  positive	  MHC	  II	  HLA-­‐DRB1	  alleles.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   33	  
FUTURE	  WORK	  AND	  DIRECTIONS	  	  The	  data	  collected	  from	  the	  experiment	  involving	  c(HS4-­‐4)	  showed	  that	  it	  is	  capable	  of	  producing	  nitric	  oxide	  signaling	  in	  cells	  exceeding	  those	  induced	  by	  65-­‐79*0401.	  This	  has	  allowed	  our	  lab	  to	  further	  our	  work	  on	  inducing	  cell	  signaling	  by	  using	  this	  cyclic	  peptide	  as	  opposed	  to	  the	  linear	  peptide.	  This	  has	  allowed	  us	  to	  design	  experiments	  in	  which	  the	  signaling	  pathway	  can	  be	  amplified	  to	  a	  stronger	  level,	  allowing	  us	  to	  see	  the	  effects	  of	  treating	  cells	  with	  different	  peptides	  that	  may	  only	  have	  a	  weak	  effect.	  It	  has	  also	  allowed	  us	  to	  induce	  a	  signaling	  cascade	  that	  is	  more	  stable	  due	  to	  the	  nature	  of	  the	  cyclic	  peptide	  as	  opposed	  to	  linear.	  	  	  Work	  involving	  the	  calreticulin,	  began	  at	  a	  very	  basic	  stage.	  This	  work	  has	  allowed	  us	  to	  refine	  the	  procedure	  in	  which	  to	  transform	  cells	  and	  obtain	  purified	  human	  calreticulin.	  It	  has	  also	  allowed	  us	  to	  create	  a	  protocol	  and	  a	  stock	  solution	  to	  be	  used	  for	  future	  experiments.	  More	  work	  is	  still	  necessary	  with	  regards	  to	  the	  human	  calreticulin.	  	  Experiments	  involving	  human	  calreticulin	  in	  order	  to	  see	  how	  the	  concentration	  affects	  nitric	  oxide	  signaling	  must	  continue	  to	  be	  performed	  involving	  MEF-­‐K42	  cell,	  which	  is	  a	  calreticulin	  knock-­‐out	  cell	  line,	  as	  well	  as	  M1	  cell.	  In	  addition	  to	  the	  necessity	  of	  these	  experiments,	  a	  direct,	  sound	  relationship	  between	  concentration	  of	  calreticulin	  and	  nitric	  oxide	  must	  be	  provided	  in	  order	  to	  further	  our	  understanding	  of	  the	  signaling	  cascade	  that	  occurs	  to	  produce	  nitric	  oxide.	  Once	  the	  signaling	  pathway	  is	  determined,	  the	  information	  will	  be	  used	  to	  further	  study	  the	  events	  that	  occur	  in	  the	  shared-­‐epitope	  positive	  cells	  that	  lead	  to	  Rheumatoid	  Arthritis.	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